Save 25% on Semaglutide subscriptions - your proven GLP-1, delivered monthly • Save 25% on Tirzepatide subscriptions - stronger weekly support, auto-shipped • Save 25% on Retatrutide subscriptions - next-gen access with recurring savings • Save 25% on Semaglutide subscriptions - your proven GLP-1, delivered monthly • Save 25% on Tirzepatide subscriptions - stronger weekly support, auto-shipped • Save 25% on Retatrutide subscriptions - next-gen access with recurring savings • Save 25% on Semaglutide subscriptions - your proven GLP-1, delivered monthly • Save 25% on Tirzepatide subscriptions - stronger weekly support, auto-shipped • Save 25% on Retatrutide subscriptions - next-gen access with recurring savings
glp.market

Research Studies

Evidence-based insights into GLP-1 receptor agonists and their role in metabolic health. Our commitment to science-backed treatments is reflected in peer-reviewed research.

Semaglutide2021

Efficacy and Safety of Semaglutide in Weight Management

Wilding JPH, et al. • New England Journal of Medicine

A 68-week, double-blind trial involving adults with overweight or obesity showed that weekly subcutaneous semaglutide (2.4 mg) plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.

Tirzepatide2022

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff AM, et al. • New England Journal of Medicine

In adults with obesity, 2.5 mg, 5 mg, 10 mg, and 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. The safety and side-effect profile of tirzepatide was similar to that of other incretin-based therapies.

Retatrutide2023

Retatrutide: A Novel Triple Agonist for Metabolic Disease

Rosenstock J, et al. • The Lancet

Retatrutide, a single molecule that activates GIP, GLP-1, and glucagon receptors, showed substantial weight loss and improved glycemic control in adults with type 2 diabetes and obesity in a phase 2 trial.

Semaglutide2023

Long-term Cardiovascular Outcomes with Semaglutide

Marso SP, et al. • Circulation

Long-term treatment with semaglutide was associated with a lower risk of cardiovascular events in patients with type 2 diabetes who were at high cardiovascular risk.

Comparative2023

Comparative Effectiveness of GLP-1 Receptor Agonists

Blonde L, et al. • JAMA Internal Medicine

A systematic review and network meta-analysis comparing the efficacy and safety of GLP-1 receptor agonists for weight management and glycemic control in adults with obesity.

Retatrutide2024

Metabolic Effects of Triple Hormone Receptor Agonism

Thomas MK, et al. • Nature Medicine

Triple agonists targeting GIP, GLP-1, and glucagon receptors demonstrate superior metabolic benefits compared to dual agonists, with enhanced weight loss and improved insulin sensitivity.

Stay Updated

Subscribe to receive the latest research and clinical insights in metabolic health.